The first vaccine for chikungunya, an emerging mosquito-borne global health threat marked by fever and joint pain, has been granted accelerated approval by the US Food and Drug Administration (FDA). The vaccine, called Ixchiq, was granted fast-track and breakthrough-therapy designations in June, and the application has now received a priority…